176 related articles for article (PubMed ID: 28533114)
1. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase.
Kurasawa O; Homma M; Oguro Y; Miyazaki T; Mori K; Uchiyama N; Iwai K; Ohashi A; Hara H; Yoshida S; Cho N
Bioorg Med Chem; 2017 Jul; 25(14):3658-3670. PubMed ID: 28533114
[TBL] [Abstract][Full Text] [Related]
2. Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones.
Kurasawa O; Oguro Y; Miyazaki T; Homma M; Mori K; Iwai K; Hara H; Skene R; Hoffman I; Ohashi A; Yoshida S; Ishikawa T; Cho N
Bioorg Med Chem; 2017 Apr; 25(7):2133-2147. PubMed ID: 28284870
[TBL] [Abstract][Full Text] [Related]
3. Discovery of XL413, a potent and selective CDC7 inhibitor.
Koltun ES; Tsuhako AL; Brown DS; Aay N; Arcalas A; Chan V; Du H; Engst S; Ferguson K; Franzini M; Galan A; Holst CR; Huang P; Kane B; Kim MH; Li J; Markby D; Mohan M; Noson K; Plonowski A; Richards SJ; Robertson S; Shaw K; Stott G; Stout TJ; Young J; Yu P; Zaharia CA; Zhang W; Zhou P; Nuss JM; Xu W; Kearney PC
Bioorg Med Chem Lett; 2012 Jun; 22(11):3727-31. PubMed ID: 22560567
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-
Kurasawa O; Miyazaki T; Homma M; Oguro Y; Imada T; Uchiyama N; Iwai K; Yamamoto Y; Ohori M; Hara H; Sugimoto H; Iwata K; Skene R; Hoffman I; Ohashi A; Nomura T; Cho N
J Med Chem; 2020 Feb; 63(3):1084-1104. PubMed ID: 31895562
[TBL] [Abstract][Full Text] [Related]
5. Aminopyrimidinone cdc7 kinase inhibitors.
Woods KW; Lai C; Miyashiro JM; Tong Y; Florjancic AS; Han EK; Soni N; Shi Y; Lasko L; Leverson JD; Johnson EF; Shoemaker AR; Penning TD
Bioorg Med Chem Lett; 2012 Mar; 22(5):1940-3. PubMed ID: 22326396
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
Reichelt A; Bailis JM; Bartberger MD; Yao G; Shu H; Kaller MR; Allen JG; Weidner MF; Keegan KS; Dao JH
Eur J Med Chem; 2014 Jun; 80():364-82. PubMed ID: 24793884
[TBL] [Abstract][Full Text] [Related]
7. Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.
Young WB; Barbosa J; Blomgren P; Bremer MC; Crawford JJ; Dambach D; Gallion S; Hymowitz SG; Kropf JE; Lee SH; Liu L; Lubach JW; Macaluso J; Maciejewski P; Maurer B; Mitchell SA; Ortwine DF; Di Paolo J; Reif K; Scheerens H; Schmitt A; Sowell CG; Wang X; Wong H; Xiong JM; Xu J; Zhao Z; Currie KS
Bioorg Med Chem Lett; 2015 Mar; 25(6):1333-7. PubMed ID: 25701252
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors.
Irie T; Asami T; Sawa A; Uno Y; Hanada M; Taniyama C; Funakoshi Y; Masai H; Sawa M
Eur J Med Chem; 2017 Apr; 130():406-418. PubMed ID: 28279847
[TBL] [Abstract][Full Text] [Related]
9. The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.
Harrington PE; Bourbeau MP; Fotsch C; Frohn M; Pickrell AJ; Reichelt A; Sham K; Siegmund AC; Bailis JM; Bush T; Escobar S; Hickman D; Heller S; Hsieh F; Orf JN; Rong M; San Miguel T; Tan H; Zalameda L; Allen JG
Bioorg Med Chem Lett; 2013 Dec; 23(23):6396-400. PubMed ID: 24120542
[TBL] [Abstract][Full Text] [Related]
10. N-substituted azaindoles as potent inhibitors of Cdc7 kinase.
Bryan MC; Falsey JR; Frohn M; Reichelt A; Yao G; Bartberger MD; Bailis JM; Zalameda L; Miguel TS; Doherty EM; Allen JG
Bioorg Med Chem Lett; 2013 Apr; 23(7):2056-60. PubMed ID: 23481650
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
[TBL] [Abstract][Full Text] [Related]
12. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency.
Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ
Bioorg Med Chem Lett; 2009 Aug; 19(16):4878-81. PubMed ID: 19616945
[TBL] [Abstract][Full Text] [Related]
13. 6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.
Uehara F; Shoda A; Aritomo K; Fukunaga K; Watanabe K; Ando R; Shinoda M; Ueno H; Kubodera H; Sunada S; Saito K; Kaji T; Asano S; Eguchi J; Yuki S; Tanaka S; Yoneyama Y; Niwa T
Bioorg Med Chem Lett; 2013 Dec; 23(24):6928-32. PubMed ID: 24094818
[TBL] [Abstract][Full Text] [Related]
14. 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
Shafer CM; Lindvall M; Bellamacina C; Gesner TG; Yabannavar A; Jia W; Lin S; Walter A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4482-5. PubMed ID: 18672368
[TBL] [Abstract][Full Text] [Related]
15. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
16. Pyrimidine-based pyrazoles as cyclin-dependent kinase 2 inhibitors: Design, synthesis, and biological evaluation.
Vekariya MK; Vekariya RH; Brahmkshatriya PS; Shah NK
Chem Biol Drug Des; 2018 Sep; 92(3):1683-1691. PubMed ID: 29767460
[TBL] [Abstract][Full Text] [Related]
17. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY
EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817
[TBL] [Abstract][Full Text] [Related]
19. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ
ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
